Hepatitis C
Showing NaN - NaN of 64
Cardiovascular Diseases, Hepatitis C, Hiv Trial in Washington, Baltimore (Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac
Active, not recruiting
- Cardiovascular Diseases
- +2 more
- Elbasvir / Grazoprevir Oral Tablet [Zepatier]
- Cardiac MRI
-
Washington, District of Columbia
- +1 more
Feb 1, 2023
Hepatitis C Trial in Baltimore (Patient-Centered Electronic App)
Recruiting
- Hepatitis C
- Patient-Centered Electronic App
-
Baltimore, MarylandJohns Hopkins University
Mar 29, 2022
Hepatitis C Trial in Denver, Baltimore, Jackson (HCV Screening)
Enrolling by invitation
- Hepatitis C
- HCV Screening
-
Denver, Colorado
- +2 more
Feb 25, 2022
Hepatitis C in HIV Infected Injection Drug Users (IDUs)
Completed
- HIV Infection
- Hepatitis C
-
Baltimore, MarylandJohns Hopkins Hospital
Feb 17, 2022
Renal Failure Chronic, Hepatitis C Trial in United States (glecaprevir/pibrentasvir treatment)
Completed
- Renal Failure Chronic
- Hepatitis C
- glecaprevir/pibrentasvir treatment
-
Chicago, Illinois
- +6 more
Jan 18, 2022
Hepatitis C, HIV, Risk Reduction Behavior Trial in Baltimore (Peer Mentor)
Completed
- Hepatitis C
- +2 more
- Peer Mentor
-
Baltimore, MarylandLighhouse Studies @ Peer Point
Jan 19, 2022
The HOPE Study: Characterizing Patients With Hepatitis B and C
Recruiting
- Hepatitis B, Chronic
- Hepatitis C
- Blood draws
- +4 more
-
Washington, District of Columbia
- +3 more
Jan 3, 2022
End Stage Renal Disease, Hepatitis C Trial in Baltimore (Glecaprevir/pibrentasvir)
Active, not recruiting
- End Stage Renal Disease
- Hepatitis C
-
Baltimore, MarylandJohns Hopkins Hospital
Dec 7, 2021
Hepatitis C Trial in Worldwide (SOF/VEL for 6 weeks, SOF/VEL for 12 weeks)
Completed
- Hepatitis C
- SOF/VEL for 6 weeks
- SOF/VEL for 12 weeks
-
Baltimore, Maryland
- +24 more
Nov 22, 2021
HIV, Hepatitis C Trial in Puerto Rico, United States (Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin
Terminated
- HIV Infections
- Hepatitis C
- Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)
- +2 more
-
Birmingham, Alabama
- +15 more
Nov 2, 2021
HIV, Hepatitis C Trial in Puerto Rico, United States (Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC))
Completed
- HIV Infections
- Hepatitis C
- Pegylated-Interferon Alfa 2b (PEG-IFN)
- +2 more
-
Birmingham, Alabama
- +42 more
Nov 2, 2021
Hepatitis C Trial in Puerto Rico, United States (ITX 5061, Placebo ITX 5061)
Completed
- Hepatitis C
- ITX 5061
- Placebo ITX 5061
-
Birmingham, Alabama
- +9 more
Oct 28, 2021
End Stage Renal Disease, Hepatitis C Trial in Baltimore (300mg glecaprevir/pibrentasivir 120mg)
Completed
- End Stage Renal Disease
- Hepatitis C
- 300mg glecaprevir/pibrentasivir 120mg
-
Baltimore, MarylandJohns Hopkins University
Sep 21, 2021
Hepatitis C, Renal Insufficiency, Chronic, Disorder of Transplanted Kidney Trial in Baltimore (Post-transplant Grazoprevir and
Active, not recruiting
- Hepatitis C
- +2 more
- Post-transplant Grazoprevir and Elbasvir
-
Baltimore, MarylandUniversity of Maryland Medical Center
Oct 5, 2021
Hepatitis C Trial in Baltimore (Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid))
Not yet recruiting
- Hepatitis C
- Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)
-
Baltimore, MarylandJohns Hopkins University
Oct 6, 2021
Direct Acting Antiviral-Post Authorization Safety Study
Completed
- Hepatitis C
- Hepatocellular Carcinoma
-
Phoenix, Arizona
- +61 more
Jul 1, 2021
Hepatitis C, HIV, AIDS Trial in United States (Control Group, Care Facilitation Group)
Completed
- Hepatitis C
- +3 more
- Control Group
- Care Facilitation Group
-
Birmingham, Alabama
- +10 more
Jul 21, 2020
Hepatitis C, HCV Trial in United States (Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet)
Completed
- Hepatitis C
- HCV
- Glecaprevir/Pibrentasvir (G/P) 300mg/120mg
- Ribavirin 200Mg Tablet
-
Palo Alto, California
- +30 more
Feb 17, 2020
Subjects Who Participated inPrevious Asunaprevir and/or
Completed
- Hepatitis C
- Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
-
Montgomery, Alabama
- +160 more
Nov 26, 2019
Hepatitis C, Human Immunodeficiency Virus Trial in Baltimore (Maraviroc)
Completed
- Hepatitis C
- Human Immunodeficiency Virus
-
Baltimore, MarylandInstitute of Human Virology at the University of Maryland School
Aug 15, 2019
Hepatitis C Trial in Baltimore (Direct Acting Antivirals)
Withdrawn
- Hepatitis C
- Direct Acting Antivirals
-
Baltimore, MarylandUniversity of Maryland Medical Center
Jul 1, 2019